Sponsor content
844 result(s) found, displaying 421 to 430
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2022
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2022
-
Cancellation or suspensionRegulatory action due to Under subsection 29D(1)(b); it is likely there are grounds for cancelling this medicine from the ARTG under section 30(2)(a) on the basis that the quality of the goods is unacceptable., effective 29/01/2022
-
Prescription medicine decision summaryTGA decision: Bevacip/Bevaciptin (bevacizumab) is approved to treat various types of cancers.
-
Prescription medicine registrationActive ingredients: bevacizumab.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PHENYLIP phenylephrine hydrochloride 10 mg / 1 mL injection USP vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for VASOPHEN phenylephrine hydrochloride 10 mg / 1 mL injection USP vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for PHENYLEPHRINE CIPLA phenylephrine hydrochloride 10 mg / 1 mL injection USP vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for CIPLA LENALIDOMIDE lenalidomide 20 mg capsule blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LENALIMID lenalidomide 25 mg capsule blister pack.